Influence of different image-guided tracking methods upon the local efficacy of CyberKnife treatment in lung tumors.

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：:Malignant pleural mesothelioma is an extremely aggressive neoplasm of the pleura mainly attributable to asbestos exposure. Conventional medical, physical, and surgical treatments and their combinations are basically ineffective and just a few subjects experience some benefit. No definite guidelines can be provided in ...

journal_title：Thoracic cancer

authors： Ambrogi V,Mineo TC,Multidisciplinary Tor Vergata University Study Group for Malignant Pleural Mesothelioma.

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC pat...

journal_title：Thoracic cancer

authors： Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

更新日期：2019-11-01 00:00:00

abstract：BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

journal_title：Thoracic cancer

authors： Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

journal_title：Thoracic cancer

authors： Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumor, associated with poor prognosis. There is a lack of information about the clinical and pathological features related with survival in the Latin American population. METHODS:The MeSO-CLICaP registry identified 302 patients with advanced MPM diagnose...

journal_title：Thoracic cancer

authors： Rojas L,Cardona AF,Trejo-Rosales R,Zatarain-Barrón ZL,Ramírez-Tirado LA,Ruiz-Patiño A,Campos Gómez S,Corrales L,Oblitas G,Bacon L,Martín C,de Lima VCC,Freitas HC,Mas L,Vargas C,Carranza H,Otero J,Pérez MA,González L,

更新日期：2019-03-01 00:00:00

abstract：:Fundamental treatment for papillary thyroid carcinoma (PTC) involves total or subtotal thyroidectomy. Iodine-131 ((131)I) is routinely utilized to target remnant thyroid cancer and metastasis after thyroidectomy. The effectiveness of other therapeutic modalities remains unsatisfactory; thus, these patients have a poor...

journal_title：Thoracic cancer

authors： Wang HJ,Yao JM,Zhang ZW,Zhao JY,Shang HX,Liao L,Dong JJ

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Lung cancer is a disease with a poor prognosis and psychological impact. Lung cancer causes both physical and psychological burdens on patients, and financial burdens on families and society. The aim of this study was to examine the relationship between depression and influencing factors in non-small-cell lu...

journal_title：Thoracic cancer

authors： Shi Y,Gu F,Hou LL,Hu YQ

更新日期：2015-05-01 00:00:00

abstract：BACKGROUND:  The 12th National Lung Cancer Academic Conference was held in Wu Han, China in 2011. METHODS:  The content of the conference involved recent research achievements and progress in the field of lung cancer, including the epidemiology of lung cancer and molecules, new methods and technology for early-screeni...

journal_title：Thoracic cancer

authors： Liu Y,Chen G,Qiu X,Chen J,Zhou Q

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:The five-year survival rate of lung adenocarcinoma patients (LUAD) is very low,and the methods of predicting survival are a great obstacle for LUAD therapies. Endothelin receptor type B (EDNRB) gene is associated with tumorigenesis. In this study, we aimed to evaluate the predictive value of EDNRB on LUAD. ...

journal_title：Thoracic cancer

authors： Wei F,Ge Y,Li W,Wang X,Chen B

更新日期：2020-07-01 00:00:00

abstract：:A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

journal_title：Thoracic cancer

authors： Wang H

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

journal_title：Thoracic cancer

authors： Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

journal_title：Thoracic cancer

authors： Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

更新日期：2020-10-01 00:00:00

abstract：:In recent years, studies have found that E2F1, a downstream effector of caveolin-1 (Cav-1), participates in tumor cell metabolic reprogramming. E2F1 modulates mitochondrial fusion and mitophagy. Bioinformatic analysis has identified the E2F1-MFN2 axis as a regulator of mitophagy. Our data establish a new novel paradig...

journal_title：Thoracic cancer

authors： Shen C,Chen X,Xiao K,Che G

更新日期：2020-06-01 00:00:00

abstract：:A clinical trial of immune checkpoint inhibitors for advanced non-small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evidence supports the efficacy of immune checkpoint inhibitors as neoadjuv...

journal_title：Thoracic cancer

authors： Sumi T,Uehara H,Masaoka T,Tada M,Keira Y,Kamada K,Shijubou N,Yamada Y,Nakata H,Mori Y,Chiba H

更新日期：2020-11-01 00:00:00

abstract：:A squamous cell lung cancer patient was treated with pneumonectomy. A recurrent lung cancer (adenocarcinoma) was found 45 months later and successfully biopsied and treated with microwave ablation. After 18 months of follow up, no evidence of tumor recurrence was observed. ...

journal_title：Thoracic cancer

authors： Wei Z,Wang J,Ye X,Yang X,Huang G

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...

journal_title：Thoracic cancer

authors： Darras M,Ojanguren A,Forster C,Zellweger M,Perentes JY,Krueger T,Gonzalez M

更新日期：2020-12-03 00:00:00

abstract：BACKGROUND:To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non-small-cell lung cancer (NSCLC). METHODS:Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two gro...

journal_title：Thoracic cancer

authors： Nie K,Zhang Z,You Y,Zhuang X,Zhang C,Ji Y

更新日期：2020-01-01 00:00:00

abstract：:Patients with EGFR-mutated non-small cell lung cancer (NSCLC) exhibit resistance to EGFR-tyrosine kinase inhibitors (TKIs) within 9-14 months of therapy. Recently, EGFR-mutated NSCLC has demonstrated the potential for heterogeneity; therefore, the manner of clonal heterogeneity may impact the duration of progression-f...

journal_title：Thoracic cancer

authors： Okuma Y,Morikawa K,Tanaka H,Yokoyama T,Itani H,Horiuchi K,Nakagawa H,Takahashi N,Bessho A,Soejima K,Kishi K,Togashi A,Kanai Y,Ueda K,Horimoto K,Matsutani N,Seki N

更新日期：2019-02-01 00:00:00

abstract：BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...

journal_title：Thoracic cancer

authors： Gil HI,Choe J,Jeong BH,Um SW,Jeon K,Hahn JY,Kim H,Kwon OJ,Chang YS,Lee K

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Our previous study showed that SUMO1 expression is closely related to progression in non-small cell lung cancer (NSCLC); however, the function of SUMO1 in NSCLC has not yet been well elucidated. METHODS:SUMO1 was enhanced or silenced in two NSCLC cell lines by using either forced SUMO1 expression or short h...

journal_title：Thoracic cancer

authors： Ke C,Zhu K,Sun Y,Ni Y,Zhang Z,Li X

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:MicroRNA-128 (miR-128) serves as a regulator by inducing cancer cell apoptosis, differentiation, the epithelial-to-mesenchymal transition process, and tumor growth by mediating different targets. NIMA-related kinase 2 (NEK2) is aberrantly expressed in lung cancer. The miR-128/NEK2 pathway has been reported t...

journal_title：Thoracic cancer

authors： Zhao D,Han W,Liu X,Cui D,Chen Y

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...

journal_title：Thoracic cancer

authors： Zhang YW,Chen QQ,Cao J,Xu LQ,Tang X,Wang J,Zhang J,Dong LX

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Breast cancer (BC) is a common cancer in women worldwide. Emerging evidence has indicated that circular RNA hsa-circ_0007255 (circ_0007255) is a prognostic mediator in BC progression. However, the functional role of circ_0007255 needs to be determined. METHODS:The expression of circ_0007255, microRNA (miR)-...

journal_title：Thoracic cancer

authors： Jia Q,Ye L,Xu S,Xiao H,Xu S,Shi Z,Li J,Chen Z

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

journal_title：Thoracic cancer

authors： Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

更新日期：2021-01-06 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：:Tyrosine kinase inhibitors are used as first-line treatment for non-small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, next-generation sequen...

journal_title：Thoracic cancer

authors： Onozawa H,Saito H,Sunami K,Kubo T,Yamamoto N,Kasajima R,Ohtsu T,Hiroshima Y,Kanamori H,Yokose T,Miyagi Y

更新日期：2020-12-01 00:00:00